Abstract Search

Background: Hypoparathyroidism (HP), a condition of parathyroid hormone (PTH) deficiency, leads to abnormal calcium metabolism. Standard of care (SOC), ie, large amounts of calcium and active vitamin D, leads to hypercalciuria and increased calcium x phosphate. Daily Natpara, PTH(1-84), injections reduced calcium and active vitamin D doses but not 24-hour urinary calcium (uCa) excretion or incidence of hypo- and hypercalcemia due to its 3-hour half-life (Natpara label). NIH st...

0 shares

ea0073oc6.6 | Oral Communications 6: Calcium and Bone | ECE2021

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

Schwarz Peter , Rejnmark Lars , Rubin Mishaela , Vokes Tamara J. , Clarke Bart L. , Ahmed Intekhab , Palermo Andrea , Marcocci Claudio , Pagotto Cristina , Eriksen Erik , Mourya Sanchita , Markova Denka , Pihl Susanne , Shu Aimee , Beckert Michael , Khan Aliya

BackgroundHypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiologic levels of calcitriol, promoting independence from Ca and active vitamin D supplements and normalization of QoL. TransCon PTH is an investigational long-acting p...

0 shares

Endocrine Abstracts

The design and preliminary results of a phase 1 TransCon PTH trial in healthy volunteers

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

BiosciAbstracts